Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 11/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24008805 | 0.85 | CAPN1 (0.52) | CAPN1CTSB | |
| SCHEMBL23355177 | 0.82 | CAPN1 (0.58) | CAPN1CTSBITGA4 | |
| SCHEMBL29961792 | 0.81 | CAPN1 (0.58) | CAPN1L3MBTL1ITGB1ITGA4 | |
| SCHEMBL24008799 | 0.81 | CAPN1 (0.58) | CAPN1L3MBTL1ITGB1ITGA4 | |
| SCHEMBL28558990 | 0.79 | L3MBTL1 (0.41) | CAPN1L3MBTL1ITGB1ITGA4 | |
| SCHEMBL23355169 | 0.77 | CAPN1 (0.58) | CAPN1CTSBITGB1ITGA4 | |
| SCHEMBL23355192 | 0.75 | ITGA4 (0.56) | CAPN1ITGB1ITGA4 | |
| SCHEMBL24862871 | 0.75 | CAPN1 (0.73) | CAPN1CTSB | |
| SCHEMBL24862869 | 0.75 | CAPN1 (0.69) | CAPN1CTSB | |
| SCHEMBL24008869 | 0.74 | CAPN1 (0.48) | CAPN1CTSBITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | BLADE THERAPEUTICS INC (US) | 2022-11-03 | — | — | US | disclosed |
| US-20210347727-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| EP-3820864-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | Blade Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| CN-112703188-A | Method for treating liver fibrosis using calpain inhibitor | 布莱德治疗公司 | 2021-04-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347727-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPN1, CAPNS1, CAPN2 | CAPN1 1/4885L3MBTL1 2837/4885CTSB 56/4885 |
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | CAPNS1, CAPN9, CAPN2 | CAPN1 4/4885L3MBTL1 3900/4885CTSB 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.